Phosphate homeostasis and disorders

Annals of Clinical Biochemistry

Volumn 51, Issue 6, 2014, Pages 631-656

  Manghat, P ^a   Sodi, R ^b   Swaminathan, R ^c  

^a DARENT VALLEY HOSPITAL   (United Kingdom)

^b NHS LANARKSHIRE   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

analytes; Electrolytes; FGF23; phosphate

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CEFOTETAN; DIURETIC AGENT; ESTROGEN; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; IFOSFAMIDE; IMATINIB; INSULIN; IRON POLYMALTOSE; KERATINOCYTE GROWTH FACTOR; LANTHANUM CARBONATE; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; NICOTINIC ACID; PARACETAMOL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; RAPAMYCIN; SALICYLIC ACID; SECRETED FRIZZLED RELATED PROTEIN 4; SEVELAMER CARBONATE; SODIUM CHLORIDE; TENOFOVIR; FIBROBLAST GROWTH FACTOR;

ALCOHOLISM; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATAEMIC RICKETS; CARDIOVASCULAR DISEASE; DENT DISEASE; DIABETIC KETOACIDOSIS; DIETARY INTAKE; DRUG INDUCED DISEASE; GENETIC DISORDER; HEMODIALYSIS; HEREDITARY HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; INTESTINE ABSORPTION; KIDNEY TRANSPLANTATION; LIVER SURGERY; META ANALYSIS (TOPIC); NONHUMAN; ONCOGENIC OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PHOSPHATE URINE LEVEL; PSEUDOHYPERPHOSPHATEMIA; PSEUDOHYPOPHOSPHATEMIA; REVIEW; URINARY EXCRETION; ADVERSE EFFECTS; BLOOD; CHRONIC DISEASE; HOMEOSTASIS; HYPOPHOSPHATASIA; METABOLISM; URINE;

CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; HYPERPHOSPHATEMIA; HYPOPHOSPHATASIA; KIDNEY TRANSPLANTATION; PARATHYROID HORMONE; PHOSPHATES;

EID: 84908539785     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563214521399     Document Type: Review

References (276)

1. Giachelli CM,Jono S,Shioi A, et al.Vascular calcification and inorganic phosphate.Am J Kidney Dis. 2001;38:S34-S37
2. Hu MS,Kayne LH,Jamgotchian N, et al.Paracellular phosphate absorption in rat colon: a mechanism for enema-induced hyperphosphatemia.Miner Electrolyte Metab. 1997;23:7-12
3. Sabbagh Y,O'Brien SP,Song W, et al.Intestinal NPT2b plays a major role in phosphate absorption and homeostasis.J Am Soc Nephrol. 2009;20:2348-2358
4. Sabbagh Y,Giral H,Caldas Y, et al.Intestinal phosphate transport.Adv Chronic Kidney Dis. 2011;18:85-90
5. Murer H,Forster I,Biber J.The sodium phosphate cotransporter family SLC34.Pflugers Arch. 2004;447:763-767
6. Xu H,Bai L,Collins JF, et al.Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1, 25-(OH) (2) vitamin D (3).Am J Physiol Cell Physiol. 2002;282:C487-C493
7. Marks J,Debnam ES,Unwin RJ.Phosphate homeostasis and the renal-gastrointestinal axis.Am J Physiol Renal Physiol. 2010;299:F285-F296
8. Hattenhauer O,Traebert M,Murer H, et al.Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake.Am J Physiol. 1999;277:G756-G762
9. Murer H,Hernando N,Forster L, et al.Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption (plenary lecture).Mol Membr Biol. 2001;18:3-11
10. Haussler MR,Whitfield GK,Kaneko I, et al.Molecular mechanisms of vitamin D action.Calcif Tissue Int. 2013;92:77-98
11. Capuano P,Radanovic T,Wagner CA, et al.Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor- and 1alphaOHase-deficient mice.Am J Physiol Cell Physiol. 2005;288:C429-C434
12. Miyamoto K,Ito M,Kuwahata M, et al.Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23.Ther Apher Dial. 2005;9:331-335
13. Marks J,Churchill LJ,Debnam ES, et al.Matrix extracellular phosphoglycoprotein inhibits phosphate transport.J Am Soc Nephrol. 2008;19:2313-2320
14. Custer M,Lotscher M,Biber J, et al.Expression of Na-P(i) cotransport in rat kidney: localization by RT-PCR and immunohistochemistry.Am J Physiol. 1994;266:F767-F774
15. Beck L,Karaplis AC,Amizuka N, et al.Targeted inactivation of NPT2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities.Proc Natl Acad Sci U S A. 1998;95:5372-5377
16. Wagner CA,Biber J,Murer H.Of men and mice: who is in control of renal phosphate reabsorption?.J Am Soc Nephrol. 2008;19:1625-1626
17. Bergwitz C,Roslin NM,Tieder M, et al.SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis.Am J Hum Genet. 2006;78:179-192
18. Segawa H,Onitsuka A,Furutani J, et al.Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development.Am J Physiol Renal Physiol. 2009;297:F671-F678
19. Primary Disorders of Phosphate Metabolism. http://www.endotext.org/section/parathyroid/ (2013, accessed 20 January 2014).
20. Segawa H,Yamanaka S,Ito M, et al.Internalization of renal type IIc Na-Pi cotransporter in response to a high-phosphate diet.Am J Physiol Renal Physiol. 2005;288:F587-F596
21. Mulroney SE,Woda CB,Halaihel N, et al.Central control of renal sodium-phosphate (NaPi-2) transporters.Am J Physiol Renal Physiol. 2004;286:F647-F652
22. Weinman EJ,Boddeti A,Cunningham R, et al.NHERF-1 is required for renal adaptation to a low-phosphate diet.Am J Physiol Renal Physiol. 2003;285:F1225-F1232
23. Weinman EJ,Biswas R,Steplock D, et al.Increased renal dopamine and acute renal adaptation to a high-phosphate diet.Am J Physiol Renal Physiol. 2011;300:F1123-F1129
24. Lotscher M,Scarpetta Y,Levi M, et al.Rapid downregulation of rat renal Na/P(i) cotransporter in response to parathyroid hormone involves microtubule rearrangement.J Clin Invest. 1999;104:483-494
25. Forster IC,Hernando N,Biber J, et al.Proximal tubular handling of phosphate: A molecular perspective.Kidney Int. 2006;70:1548-1559
26. Prie D,Urena Torres P,Friedlander G.Latest findings in phosphate homeostasis.Kidney Int. 2009;75:882-889
27. Fukumoto S,Martin TJ.Bone as an endocrine organ.Trends Endocrinol Metab. 2009;20:230-236
28. Liu S,Guo R,Simpson LG, et al.Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.J Biol Chem. 2003;278:37419-37426
29. Itoh N,Ornitz DM.Evolution of the Fgf and Fgfr gene families.Trends Genet. 2004;20:563-569
30. Garringer HJ,Mortazavi SM,Esteghamat F, et al.Two novel GALNT3 mutations in familial tumoral calcinosis.Am J Med Genet A. 2007;143A:2390-2396
31. Shimada T,Mizutani S,Muto T, et al.Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.Proc Natl Acad Sci U S A. 2001;98:6500-6505
32. Shimada T,Hasegawa H,Yamazaki Y, et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.J Bone Miner Res. 2004;19:429-435
33. Martin A,David V,Quarles LD.Regulation and function of the FGF23/klotho endocrine pathways.Physiol Rev. 2012;92:131-155
34. Martin A,David V,Laurence JS, et al.Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.Endocrinology. 2008;149:1757-1772
35. Saito H,Maeda A,Ohtomo S, et al.Circulating FGF-23 is regulated by 1 alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo.J Biol Chem. 2005;280:2543-2549
36. Vervloet MG,van Ittersum FJ,Buttler RM, et al.Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.Clin J Am Soc Nephrol. 2011;6:383-389
37. Antoniucci DM,Yamashita T,Portale AA.Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.J Clin Endocrinol Metab. 2006;91:3144-3149
38. Kawata T,Imanishi Y,Kobayashi K, et al.Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.J Am Soc Nephrol. 2007;18:2683-2688
39. Lorenz-Depiereux B,Bastepe M,Benet-Pages A, et al.DMP1 mutations in autosomal recessive hypophosphatemia implicates a bone matrix protein in the regulation of phosphate homeostasis.Nat Genet. 2006;38:1248-1250
40. Liu S,Brown TA,Zhou J, et al.Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.J Am Soc Nephrol. 2005;16:1645-1653
41. Liu S,Rowe PS,Vierthaler L, et al.Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.J Endocrinol. 2007;192:261-267
42. Eswarakumar VP,Lax I,Schlessinger J.Cellular signaling by fibroblast growth factor receptors.Cytokine Growth Factor Rev. 2005;16:139-149
43. White KE,Cabral JM,Davis SI, et al.Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.Am J Hum Genet. 2005;76:361-367
44. Urakawa I,Yamazaki Y,Shimada T, et al.Klotho converts canonical FGF receptor into a specific receptor for FGF23.Nature. 2006;444:770-774
45. Kurosu H,Kuro-o M.The Klotho gene family and the endocrine fibroblast growth factors.Curr Opin Nephrol Hypertens. 2008;17:368-372
46. Yan X,Yokote H,Jing X, et al.Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells.Genes Cells. 2005;10:489-502
47. Kurosu H,Ogawa Y,Miyoshi M, et al.Regulation of fibroblast growth factor-23 signaling by klotho.J Biol Chem. 2006;10 (281): 6120-6123
48. Li SA,Watanabe M,Yamada H, et al.Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice.Cell Struct Funct. 2004;29:91-99
49. Ornitz DM,Marie PJ.FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease.Genes Dev. 2002;16:1446-1465
50. Christov M,Koren S,Yuan Q, et al.Genetic ablation of sfrp4 in mice does not affect serum phosphate homeostasis.Endocrinology. 2011;152:2031-2036
51. Rowe PS,de Zoysa PA,Dong R, et al.MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.Genomics. 2000;67:54-68
52. Berndt T,Thomas LF,Craig TA, et al.Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption.Proc Natl Acad Sci U S A. 2007;104:11085-11090
53. Levi M,Shayman JA,Abe A, et al.Dexamethasone modulates rat renal brush border membrane phosphate transporter mRNA and protein abundance and glycosphingolipid composition.J Clin Invest. 1995;96:207-216
54. de Toledo FG,Thompson MA,Bolliger C, et al.gamma-L-glutamyl-L-DOPA inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate.Kidney Int. 1999;55:1832-1842
55. Murer H,Hernando N,Forster I, et al.Proximal tubular phosphate reabsorption: molecular mechanisms.Physiol Rev. 2000;80:1373-1409
56. Risteli J, Winter WE, Kleerekoper M and Risteli L. Bone and mineral metabolism. In: Burtis CA, Ashwood ER and Bruns DE (eds) Teitz Textbook of Clinical Chemistry and Molecular Diagnostics, 5th ed. St Louis, Missouri: Elsevier Saunders, 2012: 1748–1751.
57. Fraser WD,Logue FC,Christie JP, et al.Alteration of the circadian rhythm of intact parathyroid hormone following a 96-hour fast.Clin Endocrinol (Oxf). 1994;40:523-528
58. Endres DB,Morgan CH,Garry PJ, et al.Age-related changes in serum immunoreactive parathyroid hormone and its biological action in healthy men and women.J Clin Endocrinol Metab. 1987;65:724-731
59. Gertner JM,Coustan DR,Kliger AS, et al.Pregnancy as state of physiologic absorptive hypercalciuria.Am J Med. 1986;81:451-456
60. Fraser CG,Petersen PH,Ricos C, et al.Proposed quality specifications for the imprecision and inaccuracy of analytical systems for clinical chemistry.Eur J Clin Chem Clin Biochem. 1992;30:311-317
61. Betro MG,Pain RW.Hypophosphataemia and hyperphosphataemia in a hospital population.Br Med J. 1972;1:273-276
62. Ryback RS,Eckardt MJ,Pautler CP.Clinical relationships between serum phosphorus and other blood chemistry values in alcoholics.Arch Intern Med. 1980;140:673-677
63. Larsson L,Rebel K,Sorbo B.Severe hypophosphatemia–a hospital survey.Acta Med Scand. 1983;214:221-223
64. King AL,Sica DA,Miller G, et al.Severe hypophosphatemia in a general hospital population.South Med J. 1987;80:831-835
65. Daily WH,Tonnesen AS,Allen SJ.Hypophosphatemia – incidence, etiology, and prevention in the trauma patient.Crit Care Med. 1990;18:1210-1214
66. Calvo MS,Eastell R,Offord KP, et al.Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis.J Clin Endocrinol Metab. 1991;72:69-76
67. Zazzo JF,Troche G,Ruel P, et al.High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function.Intensive Care Med. 1995;21:826-831
68. Marik PE,Bedigian MK.Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study.Arch Surg. 1996;131:1043-1047
69. Barak V,Schwartz A,Kalickman I, et al.Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines.Am J Med. 1998;104:40-47
70. Pomposelli JJ,Pomfret EA,Burns DL, et al.Life-threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation.Liver Transpl. 2001;7:637-642
71. Kilic O,Demirkol D,Ucsel R, et al.Hypophosphatemia and its clinical implications in critically ill children: a retrospective study.J Crit Care. 2012;27:474-479
72. Santana e Meneses JF,Leite HP,de Carvalho WB, et al.Hypophosphatemia in critically ill children: prevalence and associated risk factors.Pediatr Crit Care Med. 2009;10:234-238
73. de Menezes FS,Leite HP,Fernandez J, et al.Hypophosphatemia in children hospitalized within an intensive care unit.J Intensive Care Med. 2006;21:235-239
74. Sumukadas D,Jenkinson F,Witham MD.Associations and consequences of hypophosphataemia in older hospitalised women.Age Ageing. 2009;38:112-115
75. Kagansky N,Levy S,Koren-Morag N, et al.Hypophosphataemia in old patients is associated with the refeeding syndrome and reduced survival.J Intern Med. 2005;257:461-468
76. Cohen J,Kogan A,Sahar G, et al.Hypophosphatemia following open heart surgery: incidence and consequences.Eur J Cardiothorac Surg. 2004;26:306-310
77. Loghmani S,Maracy MR,Kheirmand R.Serum phosphate level in burn patients.Burns. 2010;36:1112-1115
78. Kilic O,Demirkol D,Ucsel R, et al.Hypophosphatemia and its clinical implications in critically ill children: a retrospective study.J Crit Care. 2012;27:474-479
79. Yang HT,Yim H,Cho YS, et al.Change of serum phosphate level and clinical outcome of hypophosphatemia in massive burn patient.J Trauma Acute Care Surg. 2012;73:1298-1302
80. Yoshimatsu S,Hossain MI,Islam MM, et al.Hypophosphatemia among severely malnourished children with sepsis in Bangladesh.Pediatr Int. 2012;30:491-494
81. Datta BN,Stone MD.Hyperventilation and hypophosphataemia.Ann Clin Biochem. 2009;46:170-171
82. Zeki S,Culkin A,Gabe SM, et al.Refeeding hypophosphataemia is more common in enteral than parenteral feeding in adult in patients.Clin Nutr. 2011;30:365-368
83. Swaminathan R,Bradley P,Morgan DB, et al.Hypophosphatemia in surgical patients.Surg Gynecol Obstet. 1979;148:448-454
84. Skipper A.Refeeding syndrome or refeeding hypophosphatemia: a systematic review of cases.Nutr Clin Pract. 2012;27:34-40
85. Fuentebella J,Kerner JA.Refeeding syndrome.Pediatr Clin North Am. 2009;56:1201-1210
86. Elisaf MS,Siamopoulos KC.Mechanisms of hypophosphataemia in alcoholic patients.Int J Clin Pract. 1997;51:501-503
87. Camp MA,Allon M.Severe hypophosphatemia in hospitalized patients.Miner Electrolyte Metab. 1990;16:365-368
88. Harmelin DL,Martin FI,Wark JD.Antacid-induced phosphate depletion syndrome presenting as nephrolithiasis.Aust N Z J Med. 1990;20:803-805
89. Shields HM.Rapid fall of serum phosphorus secondary to antacid therapy.Gastroenterology. 1978;75:1137-1141
90. Shen T,Braude S.Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation.Intern Med J. 2012;42:1347-1350
91. Spicek-Macan J,Hodoba N,Kolaric N, et al.Immeasurable levels of serum phosphate – an unidentified cause of respiratory failure in a diabetic patient.Coll Antropol. 2010;34:1457-1460
92. Harsch HH.Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases.J Clin Psychiatry. 1987;48:328-333
93. Seitz DP.Hypophosphatemia and neuroleptic malignant syndrome.J Clin Psychopharmacol. 2007;27:302-303
94. Brasier AR,Nussbaum SR.Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery.Am J Med. 1988;84:654-660
95. Witteveen J,van Thiel S,Romijn JA, et al.Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism. A systemic review of the literature.Eur J Endocrinol. 2013;168:R45-R53
96. Goldfarb M,Gondek SS,Lim SM, et al.Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin.World J Surg. 2012;36:1314-1319
97. Knochel JP,Caskey JH.The mechanism of hypophosphatemia in acute heat stroke.JAMA. 1977;238:425-426
98. Chong WH,Molinolo AA,Chen CC, et al.Tumor-induced osteomalacia.Endocr Relat Cancer. 2011;18:R53-R77
99. Fiaccadori E,Coffrini E,Ronda N, et al.Hypophosphatemia in course of chronic obstructive pulmonary disease. Prevalence, mechanisms, and relationships with skeletal muscle phosphorus content.Chest. 1990;97:857-868
100. Tsirka A,Challa,Lapatsanis PD.Red cell phosphate metabolism in preterm infants with idiopathic respiratory distress syndrome.Acta Paediatr Scand. 1990;79:763-768
101. Polderman KH,Peerdeman SM,Girbes AR.Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury.J Neurosurg. 2001;94:697-705
102. Levy LA.Severe hypophosphatemia as a complication of the treatment of hypothermia.Arch Intern Med. 1980;140:128-129
103. Aibiki M,Kawaguchi S,Maekawa N.Reversible hypophosphatemia during moderate hypothermia therapy for brain-injured patients.Crit Care Med. 2001;29:1726-1730
104. Mohseni M,Chiota N,Roy A, et al.Severe hypophosphatemia and acute neurologic dysfunction in a marathon runner.Clin J Sport Med. 2011;21:269-270
105. Baum M.The Fanconi syndrome of cystinosis: insights into the pathophysiology.Pediatr Nephrol. 1998;12:492-497
106. Morgan HG,Stewart WK,Lowe KG, et al.Wilson's disease and the Fanconi syndrome.Q J Med. 1962;31:361-384
107. Lacy MQ,Gertz MA.Acquired Fanconi's syndrome associated with monoclonal gammopathies.Hematol Oncol Clin North Am. 1999;13:1273-1280
108. Lee HW,Suh KS,Kim J, et al.Hypophosphatemia after live donor right hepatectomy.Surgery. 2008;144:448-453
109. Datta HK,Malik M,Neely RD.Hepatic surgery-related hypophosphatemia.Clin Chim Acta. 2007;380:13-23
110. Lin SH,Lin YF.Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis.Am J Kidney Dis. 2001;37:620-623
111. Norris KC,Levine B,Ganesan K.Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia.Am J Kidney Dis. 1996;28:270-273
112. Wollner A,Shalit M,Brezis M.Tumor genesis syndrome. Hypophosphatemia accompanying Burkitt's lymphoma cell leukemia.Miner Electrolyte Metab. 1986;12:173-175
113. Barak V,Schwartz A,Kalickman I, et al.Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines.Am J Med. 1998;104:40-47
114. Lewis DJ.Hypophosphataemia: a feature of malaria?.Br Med J (Clin Res Ed). 1987;295:416-417
115. Davis TM,Pukrittayakamee S,Woodhead JS, et al.Calcium and phosphate metabolism in acute falciparum malaria.Clin Sci (Lond). 1991;81:297-304
116. Ayoola OO,Fawole OI,Omotade OO.Calcium and phosphate levels in Nigerian children with malaria.Ann Trop Paediatr. 2005;25:303-306
117. Brown GR,Greenwood JK.Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill.Ann Pharmacother. 1994;28:626-632
118. Liamis G,Milionis HJ,Elisaf M.Medication-induced hypophosphatemia: a review.QJM. 2010;103:449-459
119. Hall AM.Update on tenofovir toxicity in the kidney.Pediatr Nephrol. 2013;28:1011-1023
120. Law ST,Li KK,Ho YY.Acquired Fanconi syndrome associated with prolonged Adefovir Dipivoxil therapy in a chronic hepatitis B patient.Am J Ther. 2013;20:e713-e716
121. Day SL,Leake Date HA,Bannister A, et al.Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.J Acquir Immune Defic Syndr. 2005;38:301-304
122. Labarga P,Barreiro P,Martin-Carbonero L, et al.Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.AIDS. 2009;23:689-696
123. Cooper RD,Wiebe N,Smith N, et al.Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.Clin Infect Dis. 2010;51:496-505
124. Tataranni T,Biondi G,Cariello M, et al.Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression.Am J Transplant. 2011;11:1656-1664
125. Stohr W,Paulides M,Bielack S, et al.Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.Pediatr Blood Cancer. 2007;48:447-452
126. Oberlin O,Fawaz O,Rey A, et al.Long-term evaluation of Ifosfamide-related nephrotoxicity in children.J Clin Oncol. 2009;27:5350-5355
127. Stohr W,Paulides M,Bielack S, et al.Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.Pediatr Blood Cancer. 2007;48:447-452
128. Lee BS,Lee JH,Kang HG, et al.Ifosfamide nephrotoxicity in pediatric cancer patients.Pediatr Nephrol. 2001;16:796-799
129. Yamamoto S,Okada Y,Mori H, et al.Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.Intern Med. 2012;51:2375-2378
130. Mohammed S,Knoll S,van Amburg A, et al.Cefotetan-induced hemolytic anemia causing severe hypophosphatemia.Am J Hematol. 1994;46:369-370
131. Izzedine H,Bahleda R,Khayat D, et al.Electrolyte disorders related to EGFR-targeting drugs.Crit Rev Oncol Hematol. 2010;73:213-219
132. O'Sullivan S,Lin JM,Watson M, et al.The skeletal effects of the tyrosine kinase inhibitor nilotinib.Bone. 2011;49:281-289
133. Osorio S,Noblejas AG,Duran A, et al.Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.Am J Hematol. 2007;82:394-395
134. Maccubbin D,Tipping D,Kuznetsova O, et al.Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.Clin J Am Soc Nephrol. 2010;5:582-589
135. Mechanick JI,Liu K,Nierman DM, et al.Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.J Spinal Cord Med. 2006;29:406-412
136. Body JJ,Lortholary A,Romieu G, et al.A dose-finding study of zoledronate in hypercalcemic cancer patients.J Bone Miner Res. 1999;14:1557-1561
137. Cheer SM,Noble S.Zoledronic acid.Drugs. 2001;61:799-805
138. Itescu S,Haskell LP,Tannenberg AM.Thiazide-induced clinically significant hypophosphatemia.Clin Nephrol. 1987;27:161-162
139. Plante GE,Lafreniere MC,Tam PT, et al.Effect of indapamide on phosphate metabolism and vascular reactivity.Am J Med. 1988;84:26-30
140. Liamis G,Mitrogianni Z,Liberopoulos EN, et al.Electrolyte disturbances in patients with hyponatremia.Intern Med. 2007;46:685-690
141. Milionis HJ,Alexandrides GE,Liberopoulos EN, et al.Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure.Eur J Heart Fail. 2002;4:167-173
142. Jones AF,Harvey JM,Vale JA.Hypophosphataemia and phosphaturia in paracetamol poisoning.Lancet. 1989;2:608-609
143. Aitken JM,Hart DM,Smith DA.The effect of long-term mestranol administration on calcium and phosphorus homeostasis in oophorectomized women.Clin Sci. 1971;41:233-236
144. Citrin DL,Elson P,Kies MS, et al.Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implications.Am J Med. 1984;76:787-793
145. Faroqui S,Levi M,Soleimani M, et al.Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia.Kidney Int. 2008;73:1141-1150
146. Rago RP,Miles JM,Sufit RL, et al.Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.Cancer. 1994;73:1954-1959
147. Ho M,Bear RA,Garvey MB.Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.Cancer Treat Rep. 1976;60:1400-1402
148. Polak R,Huisman A,Sikma MA, et al.Spurious hypokalaemia and hypophosphataemia due to extreme hyperleukocytosis in a patient with a haematological malignancy.Ann Clin Biochem. 2010;47:179-181
149. Daly JA,Ertingshausen G.Direct method for determining inorganic phosphate in serum with the “CentrifiChem”.Clin Chem. 1972;18:263-265
150. Duncanson GO,Worth HG.Pseudohypophosphataemia as a result of bilirubin interference.Ann Clin Biochem. 1990;27:253-257
151. Eisenbrey AB,Mathew R,Kiechle FL.Mannitol interference in an automated serum phosphate assay.Clin Chem. 1987;33:2308-2309
152. Pivnick EK,Kerr NC,Kaufman RA, et al.Rickets secondary to phosphate depletion. A sequela of antacid use in infancy.Clin Pediatr (Phila). 1995;34:73-78
153. Lotz M,Zisman E,Bartter FC.Evidence for a phosphorus-depletion syndrome in man.N Engl J Med. 1968;278:409-415
154. Sivas F,Gunesen O,Ozoran K, et al.Osteomalacia from Mg-containing antacid: a case report of bilateral hip fracture.Rheumatol Int. 2007;27:679-681
155. Mostellar ME,Tuttle EP.Effects of alkalosis on plasma concentration and urinary excretion of inorganic phosphate in man.J Clin Invest. 1964;43:138-149
156. Paleologos M,Stone E,Braude S.Persistent, progressive hypophosphataemia after voluntary hyperventilation.Clin Sci (Lond). 2000;98:619-625
157. Guillou PJ,Morgan DB,Hill GL.Hypophosphataemia: A complication of “innocuous dextrose-saline”.Lancet. 1976;2:710-712
158. Swaminathan R,Morgan DB,Ionescu M, et al.Hypophosphataemia and its consequences in patients following open heart surgery.Anaesthesia. 1978;33:601-605
159. Boateng AA,Sriram K,Meguid MM, et al.Refeeding syndrome: treatment considerations based on collective analysis of literature case reports.Nutrition. 2010;26:156-167
160. Evenepoel P,Meijers BK,de Jonge H, et al.Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.Clin J Am Soc Nephrol. 2008;3:1829-1836
161. Evenepoel P,Meijers BK,de Jonge H, et al.Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.Clin J Am Soc Nephrol. 2008;3:1829-1836
162. Ghanekar H,Welch BJ,Moe OW, et al.Post-renal transplantation hypophosphatemia: a review and novel insights.Curr Opin Nephrol Hypertens. 2006;15:97-104
163. Sayegh J,Augusto JF,Chappard D, et al.A case of severe osteomalacia secondary to phosphate diabetes in a renal transplant recipient.Int Urol Nephrol. 2013;45:1795-1799
164. Han SY,Hwang EA,Park SB, et al.Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.Transplant Proc. 2012;44:657-660
165. Sayegh J,Augusto JF,Chappard D, et al.A case of severe osteomalacia secondary to phosphate diabetes in a renal transplant recipient.Int Urol Nephrol. 2013;45:1795-1799
166. Kazama I,Matsubara M,Michimata M, et al.Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy.Clin Exp Nephrol. 2004;8:283-287
167. Tang HL,Chu KH,Cheuk A, et al.Renal tubular acidosis and severe hypophosphataemia due to toluene inhalation.Hong Kong Med J. 2005;11:50-53
168. Loven L,Larsson J,Lennquist S, et al.Hypophosphataemia and muscle phosphate metabolism in severely injured patients.Acta Chir Scand. 1983;149:743-749
169. Nafidi O,Lapointe RW,Lepage R, et al.Mechanisms of renal phosphate loss in liver resection-associated hypophosphatemia.Ann Surg. 2009;249:824-827
170. Filik L,Karakayali H,Dalgic A, et al.Hypophosphatemia in living liver donors.Transplant Proc. 2006;38:559-561
171. Salem RR,Tray K.Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia.Ann Surg. 2005;241:343-348
172. Baquerizo A,Anselmo D,Shackleton C, et al.Phosphorus an early predictive factor in patients with acute liver failure.Transplantation. 2003;75:2007-2014
173. Yuan D,Wei YG,Chen K, et al.Hepatectomy-related hypophosphatemia may predict donor liver dysfunction in live-donor liver transplantation.Transplant Proc. 2010;42:4548-4551
174. Chong WH,Molinolo AA,Chen CC, et al.Tumor-induced osteomalacia.Endocr Relat Cancer. 2011;18:R53-R77
175. Hoffman RJ,Hoffman RS,Freyberg CL, et al.Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels.J Toxicol Clin Toxicol. 2001;39:339-344
176. Prince RL,Monk KJ,Kent GN, et al.Effects of theophylline and salbutamol on phosphate and calcium metabolism in normal subjects.Miner Electrolyte Metab. 1988;14:262-265
177. Brady HR,Ryan F,Cunningham J, et al.Hypophosphatemia complicating bronchodilator therapy for acute severe asthma.Arch Intern Med. 1989;149:2367-2368
178. Arroliga AC,Guntupalli KK,Beaver JS, et al.Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.Crit Care Med. 2009;37:1299-1307
179. Fernandez-Fernandez B,Montoya-Ferrer A,Sanz AB, et al.Tenofovir nephrotoxicity: 2011 update.AIDS Res Treat. 2011;2011:354908-354908
180. Kiser JJ,Aquilante CL,Anderson PL, et al.Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.J Acquir Immune Defic Syndr. 2008;47:298-303
181. Pushpakom SP,Liptrott NJ,Rodriguez-Novoa S, et al.Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.J Infect Dis. 2011;204:145-153
182. Okada M,Imamura K,Iida M, et al.Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.Klin Wochenschr. 1983;61:99-102
183. Yamamoto S,Okada Y,Mori H, et al.Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.Intern Med. 2012;51:2375-2378
184. Sato K,Shiraki M.Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.Endocr J. 1998;45:431-439
185. Florkowski CM,Jones AF,Guy JM, et al.Retinol binding proteinuria and phosphaturia: markers of paracetamol-induced nephrotoxicity.Ann Clin Biochem. 1994;31:331-334
186. Carpenter TO.The expanding family of hypophosphatemic syndromes.J Bone Miner Metab. 2012;30:1-9
187. Alon US.Clinical practice. Fibroblast growth factor (FGF)23: a new hormone.Eur J Pediatr. 2011;170:545-554
188. Devuyst O,Thakker RV.Dent's disease.Orphanet J Rare Dis. 2010;5:28-28
189. Haito-Sugino S,Ito M,Ohi A, et al.Processing and stability of type IIc sodium-dependent phosphate cotransporter mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria.Am J Physiol Cell Physiol. 2012;302:C1316-C1330
190. Tiosano D,Gepstein V.Vitamin D action: lessons learned from hereditary 1,25-dihydroxyvitamin-D-resistant rickets patients.Curr Opin Endocrinol Diabetes Obes. 2012;19:452-459
191. Durmaz E,Zou M,Al-Rijjal RA, et al.Clinical and genetic analysis of patients with vitamin D-dependent rickets type 1 A.Clin Endocrinol (Oxf). 2012;77:363-369
192. Collins MT,Singer FR,Eugster E.McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.Orphanet J Rare Dis. 2012;7:S4-S4
193. Thakker RV.Diseases associated with the extracellular calcium-sensing receptor.Cell Calcium. 2004;35:275-282
194. Onuchic L,Ferraz-de-Souza B,Mendonca BB, et al.Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia.J Clin Endocrinol Metab. 2012;97:1098-1103
195. Farrow EG,Imel EA,White KE.Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and alphaKlotho).Best Pract Res Clin Rheumatol. 2011;25:735-747
196. Mannstadt M,Bertrand G,Muresan M, et al.Dominant-negative GCMB mutations cause an autosomal dominant form of hypoparathyroidism.J Clin Endocrinol Metab. 2008;93:3568-3576
197. Al-Azem H,Khan AA.Hypoparathyroidism.Best Pract Res Clin Endocrinol Metab. 2012;26:517-522
198. Arnold A,Horst SA,Gardella TJ, et al.Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism.J Clin Invest. 1990;86:1084-1087
199. Hoogendam J,Farih-Sips H,Wynaendts LC, et al.Novel mutations in the parathyroid hormone (PTH)/PTH-related peptide receptor type 1 causing Blomstrand osteochondrodysplasia types I and II.J Clin Endocrinol Metab. 2007;92:1088-1095
200. Laura FS.Epidermal nevus syndrome.Handb Clin Neurol. 2013;111:349-368
201. Shankar VN,Ajila V,Kumar G.Osteoglophonic dysplasia: a case report.J Oral Sci. 2010;52:167-171
202. Yawata Y,Hebbel RP,Silvis S, et al.Blood cell abnormalities complicating the hypophosphatemia of hyperalimentation: erythrocyte and platelet ATP deficiency associated with hemolytic anemia and bleeding in hyperalimented dogs.J Lab Clin Med. 1974;84:643-653
203. Knochel JP,Barcenas C,Cotton JR, et al.Hypophosphatemia and rhabdomyolysis.J Clin Invest. 1978;62:1240-1246
204. Kumar D,McAlister FA.Rhabdomyolysis complicating unrecognized hypophosphatemia in an alcoholic patient.Can J Gastroenterol. 1999;13:165-167
205. Altuntas Y,Innice M,Basturk T, et al.Rhabdomyolysis and severe haemolytic anaemia, hepatic dysfunction and intestinal osteopathy due to hypophosphataemia in a patient after Billroth II gastrectomy.Eur J Gastroenterol Hepatol. 2002;14:555-557
206. Singhal PC,Kumar A,Desroches L, et al.Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia.Am J Med. 1992;92:458-464
207. LaCelle PL.Alteration of membrane deformability in hemolytic anemias.Semin Hematol. 1970;7:355-371
208. Melvin JD,Watts RG.Severe hypophosphatemia: a rare cause of intravascular hemolysis.Am J Hematol. 2002;69:223-224
209. Craddock PR,Yawata Y,VanSanten L, et al.Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation.N Engl J Med. 1974;290:1403-1407
210. Patel U,Sriram K.Acute respiratory failure due to refeeding syndrome and hypophosphatemia induced by hypocaloric enteral nutrition.Nutrition. 2009;25:364-367
211. Gravelyn TR,Brophy N,Siegert C, et al.Hypophosphatemia-associated respiratory muscle weakness in a general inpatient population.Am J Med. 1988;84:870-876
212. Alsumrain MH,Jawad SA,Imran NB, et al.Association of hypophosphatemia with failure-to-wean from mechanical ventilation.Ann Clin Lab Sci. 2010;40:144-148
213. Fuller TJ,Nichols WW,Brenner BJ, et al.Reversible depression in myocardial performance in dogs with experimental phosphorus deficiency.J Clin Invest. 1978;62:1194-1200
214. O'Connor LR,Wheeler WS,Bethune JE.Effect of hypophosphatemia on myocardial performance in man.N Engl J Med. 1977;297:901-903
215. Davis SV,Olichwier KK,Chakko SC.Reversible depression of myocardial performance in hypophosphatemia.Am J Med Sci. 1988;295:183-187
216. Iguchi Y,Mori K,Koike H, et al.Hypophosphataemic neuropathy during total parenteral nutrition.BMJ Case Rep. 2009;2009:bcr.08.2008.0718-bcr.08.2008.0718
217. DeFronzo RA,Lang R.Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin.N Engl J Med. 1980;303:1259-1263
218. Brunelli SM,Goldfarb S.Hypophosphatemia: clinical consequences and management.J Am Soc Nephrol. 2007;18:1999-2003
219. Suzuki S,Egi M,Schneider AG, et al.Hypophosphatemia in critically ill patients.J Crit Care. 2013;28:536.e9-e19
220. Payne RB.Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation.Ann Clin Biochem. 1998;35:201-206
221. Imel EA,Econs MJ.Approach to the hypophosphatemic patient.J Clin Endocrinol Metab. 2012;97:696-706
222. Frajewicki V,Kohan R,Abu-Ata M, et al.Intraperitoneal phosphate administration in hungry bone syndrome.Clin Nephrol. 1990;34:223-224
223. Shiber JR,Mattu A.Serum phosphate abnormalities in the emergency department.J Emerg Med. 2002;23:395-400
224. Miller DW,Slovis CM.Hypophosphatemia in the emergency department therapeutics.Am J Emerg Med. 2000;18:457-461
225. Vannatta JB,Andress DL,Whang R, et al.High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia.South Med J. 1983;76:1424-1426
226. Rosen GH,Boullata JI,O'Rangers EA, et al.Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia.Crit Care Med. 1995;23:1204-1210
227. Taylor BE,Huey WY,Buchman TG, et al.Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit.J Am Coll Surg. 2004;198:198-204
228. Stanga Z,Brunner A,Leuenberger M, et al.Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment.Eur J Clin Nutr. 2008;62:687-694
229. Carpenter TO,Imel EA,Holm IA, et al.A clinician's guide to X-linked hypophosphatemia.J Bone Miner Res. 2011;26:1381-1388
230. Crook MA.Hypophosphataemia and hypokalaemia in patients with hypomagnesaemia.Br J Biomed Sci. 1994;51:24-27
231. Dynamics in bone and cartilage metabolism. Seibel MRobins SBilezikian J, ed. Burlington, MA: Academic Press Burlington; 2006:
232. Mendoza D,Connors S,Lane C, et al.Liposomal amphotericin B as a cause of pseudohyperphosphatemia.Clin Infect Dis. 2008;46:645-646
233. Jensen GM,Bunch TH,Wolf S, et al.Erroneous determination of hyperphosphatemia (‘pseudohyperphosphatemia’) in sera of patients that have been treated with liposomal amphotericin B (AmBisome).Clin Chim Acta. 2010;411:1900-1905
234. Schiller B,Virk B,Blair M, et al.Spurious hyperphosphatemia in patients on hemodialysis with catheters.Am J Kidney Dis. 2008;52:617-620
235. Lovekar S,Chen JL.A 90-year-old man with hyperphosphatemia.Am J Kidney Dis. 2011;57:342-346
236. Larner AJ.Pseudohyperphosphatemia.Clin Biochem. 1995;28:391-393
237. Suchin EJ,Cizman B,Connolly BR, et al.Pseudohyperphosphatemia in a hyperphosphatemic hemodialysis patient.Am J Kidney Dis. 2002;40:E18-E18
238. Ladenhauf HN,Stundner O,Spreitzhofer F, et al.Severe hyperphosphatemia after administration of sodium-phosphate containing laxatives in children: case series and systematic review of literature.Pediatr Surg Int. 2012;28:805-814
239. Ori Y,Rozen-Zvi B,Chagnac A, et al.Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience.Arch Intern Med. 2012;172:263-265
240. Firwana BM,Hasan R,Hasan N, et al.Tumor lysis syndrome: a systematic review of case series and case reports.Postgrad Med. 2012;124:92-101
241. Bourke E,Yanagawa N.Assessment of hyperphosphatemia and hypophosphatemia.Clin Lab Med. 1993;13:183-207
242. Liberopoulos EN,Kei AA,Elisaf MS.Lysis syndrome during therapy of visceral leishmaniasis.Infection. 2012;40:121-123
243. Bosch X,Poch E,Grau JM.Rhabdomyolysis and acute kidney injury.N Engl J Med. 2009;361:62-72
244. Rosenberg H,Davis M,James D, et al.Malignant hyperthermia.Orphanet J Rare Dis. 2007;2:21-21
245. Melvin JD,Watts RG.Severe hypophosphatemia: a rare cause of intravascular hemolysis.Am J Hematol. 2002;69:223-224
246. Sternbach GL,Varon J.Severe hyperphosphatemia associated with hemorrhagic shock.Am J Emerg Med. 1992;10:331-332
247. Gonzalez-Parra E,Tunon J,Egido J, et al.Phosphate: a stealthier killer than previously thought?.Cardiovasc Pathol. 2012;21:372-381
248. Wolf M.Forging forward with 10 burning questions on FGF23 in kidney disease.J Am Soc Nephrol. 2010;21:1427-1435
249. Isakova T,Wahl P,Vargas GS, et al.Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Kidney Int. 2011;79:1370-1378
250. Ritz E,Gross ML.Hyperphosphatemia in renal failure.Blood Purif. 2005;23:6-9
251. Nakanishi S,Kazama JJ,Nii-Kono T, et al.Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.Kidney Int. 2005;67:1171-1178
252. Kazama JJ,Sato F,Omori K, et al.Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.Kidney Int. 2005;67:1120-1125
253. Pereira RC,Juppner H,Azucena-Serrano CE, et al.Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.Bone. 2009;45:1161-1168
254. Gutierrez OM,Mannstadt M,Isakova T, et al.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.N Engl J Med. 2008;359:584-592
255. Lee R,Weber TJ.Disorders of phosphorus homeostasis.Curr Opin Endocrinol Diab Obes. 2010;17:561-567
256. Egbuna OI,Brown EM.Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.Best Pract Res Clin Rheumatol. 2008;22:129-148
257. Parkinson DB,Thakker RV.A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism.Nat Genet. 1992;1:149-152
258. Chenouard A,Isidor B,Allain-Launay E, et al.Renal phenotypic variability in HDR syndrome: glomerular nephropathy as a novel finding.Eur J Pediatr. 2013;172:107-110
259. Domico MB,Huynh V,Anand SK, et al.Severe hyperphosphatemia and hypocalcemic tetany after oral laxative administration in a 3-month-old infant.Pediatrics. 2006;118:e1580-e1583
260. Quarles LD.Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.Exp Cell Res. 2012;318:1040-1048
261. Carey RW,Schmitt GW,Kopald HH, et al.Massive extraskeletal calcification during phosphate treatment of hypercalcemia.Arch Intern Med. 1968;122:150-155
262. Markowitz GS,Stokes MB,Radhakrishnan J, et al.Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure.J Am Soc Nephrol. 2005;16:3389-3396
263. Tentori F,Blayney MJ,Albert JM, et al.Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).Am J Kidney Dis. 2008;52:519-530
264. Foley RN,Collins AJ,Herzog CA, et al.Serum phosphorus levels associate with coronary atherosclerosis in young adults.J Am Soc Nephrol. 2009;20:397-404
265. Onufrak SJ,Bellasi A,Shaw LJ, et al.Phosphorus levels are associated with subclinical atherosclerosis in the general population.Atherosclerosis. 2008;199:424-431
266. Saab G,Whooley MA,Schiller NB, et al.Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study.Am J Kidney Dis. 2010;56:496-505
267. Ketteler M,Wolf M,Hahn K, et al.Phosphate: a novel cardiovascular risk factor.Eur Heart J. 2013;34:1099-1101
268. Ellam TJ,Chico TJ.Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease.Atherosclerosis. 2012;220:310-318
269. Jono S,McKee MD,Murry CE, et al.Phosphate regulation of vascular smooth muscle cell calcification.Circ Res. 2000;87:E10-E17
270. Shuto E,Taketani Y,Tanaka R, et al.Dietary phosphorus acutely impairs endothelial function.J Am Soc Nephrol. 2009;20:1504-1512
271. Gutierrez OM,Januzzi JL,Isakova T, et al.Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.Circulation. 2009;119:2545-2552
272. Yalin AS,Altiparmak MR,Trabulus S, et al.Calciphylaxis: a report of six cases and review of literature.Ren Fail. 2013;35:163-169
273. Rogers NM,Coates PT.Calcific uraemic arteriolopathy: an update.Curr Opin Nephrol Hypertens. 2008;17:629-634
274. Leaf DE,Wolf M.A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.Am J Kidney Dis. 2013;61:330-336
275. Ketteler M.Phosphate metabolism in CKD stages 3--5: dietary and pharmacological control.Int J Nephrol. 2011;2011:970245-970245
276. Block GA,Wheeler DC,Persky MS, et al.Effects of phosphate binders in moderate CKD.J Am Soc Nephrol. 2012;23:1407-1415